EUVIMEDEUVIMED entdecken
Open Access

β-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial Infarction

β-Blocker-Anwendung und klinische Outcomes bei Patient:innen mit COPD nach akutem Myokardinfarkt

David C LaFon, Erika S Helgeson, Sarah Lindberg, Helen Voelker, Surya P Bhatt, Richard Casaburi, Steven J Cassady, John Connett, Gerard J Criner, Umur Hatipoglu, David A Kaminsky, Ken M Kunisaki und 6 weitere

JAMA Network Open · 21.05.2024 · 7 (5) · e247535

DOI: 10.1001/jamanetworkopen.2024.7535 ↗

Auf einen Blick

Bei Patient:innen mit COPD und akutem Myokardinfarkt war eine β-Blocker-Verordnung bei Entlassung nicht mit einem erhöhten Risiko für ungünstige Outcomes verbunden.

Fragestellung

Ist eine β-Blocker-Verordnung bei Entlassung nach akutem Myokardinfarkt bei Patient:innen mit COPD mit einem erhöhten Risiko für Mortalität oder adverse kardiopulmonale Outcomes verbunden?

Methode

Prospektive longitudinale Kohortenstudie mit 6 Monaten Follow-up in 18 BLOCK-COPD-Netzwerkkrankenhäusern in den USA; Patient:innen ab 35 Jahren mit COPD und AMI nach Herzkatheterisierung.

Ergebnisse

Unter 562 Patient:innen mit COPD in der Endanalyse war die β-Blocker-Verordnung bei Entlassung nicht mit höherem Risiko verbunden: primärer Endpunkt HR 1,01 (95 %-KI 0,66–1,54), kardiovaskuläre Ereignisse HR 1,11 (95 %-KI 0,65–1,92), COPD-/Respirationsereignisse HR 0,75 (95 %-KI 0,34–1,66), Exazerbationsbehandlung RR 1,01 (95 %-KI 0,53–1,91).

Schlussfolgerung der Autor:innen

Die Autor:innen schlussfolgern, dass die β-Blocker-Verordnung bei Entlassung bei Patient:innen mit COPD und AMI nicht mit einem erhöhten Risiko für adverse Outcomes assoziiert war.

Kernaussagen

  • Keine Risikoerhöhung beim primären Endpunkt
  • Auch für kardiovaskuläre und COPD-bezogene Endpunkte kein Signal
  • Die Befunde unterstützen den Einsatz von β-Blockern nach recentem AMI bei COPD

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 21.05.2024. Verfasst von David C LaFon und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy and Critical Care Medicine, Heersink School of Medicine, The University of Alabama at Birmingham. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Adrenergic beta-Antagonists, Myocardial Infarction. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance While β-blockers are associated with decreased mortality in cardiovascular disease (CVD), exacerbation-prone patients with chronic obstructive pulmonary disease (COPD) who received metoprolol in the Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (BLOCK-COPD) trial experienced increased risk of exacerbations requiring hospitalization. However, the study excluded individuals with established indications for the drug, raising questions about the overall risk and benefit in patients with COPD following acute myocardial infarction (AMI).

Objective

To investigate whether β-blocker prescription at hospital discharge is associated with increased risk of mortality or adverse cardiopulmonary outcomes in patients with COPD and AMI. Design, Setting, and Participants This prospective, longitudinal cohort study with 6 months of follow-up enrolled patients aged 35 years or older with COPD who underwent cardiac catheterization for AMI at 18 BLOCK-COPD network hospitals in the US from June 2020 through May 2022. Exposure Prescription for any β-blocker at hospital discharge. Main Outcomes and Measures The primary outcome was time to the composite outcome of death or all-cause hospitalization or revascularization. Secondary outcomes included death, hospitalization, or revascularization for CVD events, death or hospitalization for COPD or respiratory events, and treatment for COPD exacerbations.

Results

Among 3531 patients who underwent cardiac catheterization for AMI, prevalence of COPD was 17.1% (95% CI, 15.8%-18.4%). Of 579 total patients with COPD and AMI, 502 (86.7%) were prescribed a β-blocker at discharge. Among the 562 patients with COPD included in the final analysis, median age was 70.0 years (range, 38.0-94.0 years) and 329 (58.5%) were male; 553 of the 579 patients (95.5%) had follow-up information. Among those discharged with β-blockers, there was no increased risk of the primary end point of all-cause mortality, revascularization, or hospitalization (hazard ratio [HR], 1.01; 95% CI, 0.66-1.54; P = .96) or of cardiovascular events (HR, 1.11; 95% CI, 0.65-1.92; P = .69), COPD-related or respiratory events (HR, 0.75; 95% CI, 0.34-1.66; P = .48), or treatment for COPD exacerbations (rate ratio, 1.01; 95% CI, 0.53-1.91; P = .98). Conclusions and Relevance In this cohort study, β-blocker prescription at hospital discharge was not associated with increased risk of adverse outcomes in patients with COPD and AMI. These findings support use of β-blockers in patients with COPD and recent AMI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveAdrenergic beta-AntagonistsMyocardial InfarctionHumansMaleFemaleAgedMiddle AgedProspective StudiesLongitudinal StudiesHospitalization

Substanzen

Adrenergic beta-Antagonists

Autor:innen und Institutionen

  • Division of Pulmonary, Allergy and Critical Care Medicine, Heersink School of Medicine, The University of Alabama at Birmingham.
  • UAB Lung Health Center, Heersink School of Medicine, The University of Alabama at Birmingham.
  • Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis.
  • Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, California.
  • Division of Pulmonary and Critical Care Medicine, University of Maryland, Baltimore.
  • Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

LaFon, D. C., Helgeson, E. S., Lindberg, S., Voelker, H., Bhatt, S. P., Casaburi, R., Cassady, S. J., Connett, J., Criner, G. J., Hatipoglu, U., Kaminsky, D. A., Kunisaki, K. M., Lazarus, S. C., McEvoy, C. E., Reed, R. M., Sciurba, F. C., Stringer, W., & Dransfield, M. T. (2024). β-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial Infarction. JAMA Network Open, 7(5), e247535. https://doi.org/10.1001/jamanetworkopen.2024.7535

Vancouver

LaFon DC, Helgeson ES, Lindberg S, Voelker H, Bhatt SP, Casaburi R, et al. β-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial Infarction. JAMA Network Open. 2024;7(5):e247535. doi:10.1001/jamanetworkopen.2024.7535

BibTeX
@article{LaFon2024,
  author = {LaFon, David C and Helgeson, Erika S and Lindberg, Sarah and Voelker, Helen and Bhatt, Surya P and Casaburi, Richard and Cassady, Steven J and Connett, John and Criner, Gerard J and Hatipoglu, Umur and Kaminsky, David A and Kunisaki, Ken M and Lazarus, Stephen C and McEvoy, Charlene E and Reed, Robert M and Sciurba, Frank C and Stringer, William and Dransfield, Mark T},
  title = {β-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial Infarction},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {5},
  pages = {e247535},
  doi = {10.1001/jamanetworkopen.2024.7535}
}
Kostenlos starten →